Eiger BioPharmaceuticals Inc
NASDAQ:EIGR
Eiger BioPharmaceuticals Inc
NASDAQ:EIGR
Price:
1.73 USD
-33.46%
Market Closed
Updated:
May 18, 2024
Eiger BioPharmaceuticals Inc
Operating Expenses
|
Eiger BioPharmaceuticals Inc
Operating Expenses Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Operating Expenses Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Eiger BioPharmaceuticals Inc
NASDAQ:EIGR
|
Operating Expenses
-$87.5m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-16%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Expenses
-$20.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Expenses
-$12.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-11%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Expenses
-$12.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Expenses
-$4.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-14%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Expenses
-$7.3B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-19%
|
See Also
What is Eiger BioPharmaceuticals Inc's Operating Expenses?
Operating Expenses
-87.5m
USD
-87.5m
USD
Based on the financial report for Dec 31, 2023, Eiger BioPharmaceuticals Inc's Operating Expenses amounts to -87.5m USD.
What is Eiger BioPharmaceuticals Inc's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
-16%
-16%
Over the last year, the Operating Expenses growth was 16%. The average annual Operating Expenses growth rates for Eiger BioPharmaceuticals Inc have been -12% over the past three years , -11% over the past five years , and -16% over the past ten years .
You don't have any saved screeners yet
